Compare BMEA & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | SUNS |
|---|---|---|
| Founded | 2017 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.1M | 108.7M |
| IPO Year | 2021 | N/A |
| Metric | BMEA | SUNS |
|---|---|---|
| Price | $1.27 | $7.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.83 | $8.75 |
| AVG Volume (30 Days) | ★ 566.6K | 53.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 16.17% |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $70.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.84 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $7.34 |
| 52 Week High | $2.99 | $11.78 |
| Indicator | BMEA | SUNS |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 44.47 |
| Support Level | $1.21 | $7.79 |
| Resistance Level | $1.44 | $8.18 |
| Average True Range (ATR) | 0.06 | 0.26 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 58.14 | 34.18 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.